Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Symtuza“
Suchtreffer
Begriffe & Kennungen
Symtuza · 4.8 · Immune reconstitution inflammatory syndrome In HIV infected patients with severe immune deficiency at the time
Eintrag öffnenSymtuza · 4.8 · In the Phase 3 trial of Symtuza in treatment-naïve patients, increases from baseline were observed in the fast
Eintrag öffnenSymtuza · 4.8 · In the Phase 3 trial of Symtuza in treatment-naïve patients, increases in serum creatinine and decreases in eG
Eintrag öffnenSymtuza · 4.8 · Metabolic parameters Weight and levels of blood lipids and glucose may increase during antiretroviral therapy
Eintrag öffnenSymtuza · 4.8 · Musculoskeletal abnormalities Increased creatine phosphokinase (CPK), myalgia, myositis and rarely, rhabdomyol
Eintrag öffnenSymtuza · 4.8 · Osteonecrosis Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged
Eintrag öffnenSymtuza · 4.8 · Other special populations Patients co-infected with hepatitis B and/or hepatitis C virus Limited information i
Eintrag öffnenSymtuza · 4.8 · Paediatric population The safety of Symtuza (as an FDC formulation) has not been investigated in paediatric pa
Eintrag öffnenSymtuza · 4.8 · Reductions in BMD of the spine and of the TBLH ≥ 4% have been reported in paediatric patients receiving other
Eintrag öffnenSymtuza · 4.8 · Summary of the safety profile The overall safety profile of Symtuza is based on data from a randomised, double
Eintrag öffnenSymtuza · 4.8 · Table 3 Median increase from baseline at Lipid parameter Baseline median Week 48 Week 48 Week 96* D/C/F/TAF D/
Eintrag öffnenSymtuza · 4.8 · Tabulated list of adverse reactions Adverse reactions are listed by system organ class (SOC) and frequency cat
Eintrag öffnenSymtuza · 4.8 · The most frequent (> 5%) adverse reactions reported in suppressed treatment-experienced patients (EMERALD Stud
Eintrag öffnenSymtuza · 4.8 · The most frequent (> 5%) adverse reactions reported in treatment-naïve patients in the Phase 2 (GS- US-299-010
Eintrag öffnenSymtuza · 4.8 · The safety of the components of Symtuza was also evaluated in a limited number of children aged 6 to < 12 year
Eintrag öffnenSymtuza · 4.8 · common dizziness Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, abd
Eintrag öffnenSymtuza · 4.8 · not known toxic epidermal necrolysisa, acute generalised exanthematous pustulosisa Musculoskeletal and connect
Eintrag öffnenSymtuza · 4.8 · rare drug reaction with eosinophilia and systemic symptomsa, Stevens-Johnson syndromea
Eintrag öffnenSymtuza · 4.8 · uncommon acute hepatitisa, cytolytic hepatitisa Skin and subcutaneous tissue disorders very common rash (inclu
Eintrag öffnenSymtuza · 4.8 · uncommon angioedema
Eintrag öffnen